Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PCSA 
Processa Pharmaceuticals Inc (PCSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PCSA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.1% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.87M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1 | Beta 1.52 | 52 Weeks Range 0.15 - 1.50 | Updated Date 10/15/2025 |
52 Weeks Range 0.15 - 1.50 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.31 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -102.62% | Return on Equity (TTM) -212.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4414097 | Price to Sales(TTM) - |
Enterprise Value 4414097 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 55816330 | Shares Floating 42546038 |
Shares Outstanding 55816330 | Shares Floating 42546038 | ||
Percent Insiders 12.08 | Percent Institutions 5.99 |
Upturn AI SWOT
Processa Pharmaceuticals Inc
Company Overview
History and Background
Processa Pharmaceuticals Inc. was founded in 2007. It's a clinical-stage biopharmaceutical company focused on developing next generation chemotherapeutics to improve the survival and quality of life for cancer patients.
Core Business Areas
- Next Generation Chemotherapeutics: Processa focuses on developing novel drugs and improving existing chemotherapeutics to enhance efficacy and reduce toxicity for cancer patients.
Leadership and Structure
Dr. David Young is the CEO. The company has a typical structure for a biopharmaceutical firm with departments focused on R&D, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Procetinostat: A next generation histone deacetylase (HDAC) inhibitor being developed for multiple myeloma and other hematologic malignancies. Phase 2 clinical trials are ongoing. Competitors include existing HDAC inhibitors like vorinostat and romidepsin.
- Capecitabine Clinical Trial (Off-Label): Initiating a Phase 1 clinical trial utilizing off-label capecitabine to optimize efficacy with lower doses for patients. Competitors include other chemotherapy drugs used in similar indications.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high risk, high reward drug development, stringent regulatory requirements, and increasing competition. Cancer therapeutics is a significant and growing segment.
Positioning
Processa is a small-cap company focusing on niche oncology markets with the goal of improving existing treatments and addressing unmet needs. Its competitive advantage lies in its proprietary drug candidates and focus on optimization.
Total Addressable Market (TAM)
The global cancer therapeutics market is estimated to be worth hundreds of billions of USD. Processa is focused on specific cancer types. Procetinostat is targeting areas that are not covered by standard treatements.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Proprietary drug candidates
- Focus on unmet medical needs
- Potential for improved efficacy and reduced toxicity compared to existing treatments
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from larger pharmaceutical companies
- High risk of drug development failure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from new therapies
- Patent expiration
Competitors and Market Share
Key Competitors
- MRTX
- GILD
- BMRN
Competitive Landscape
Processa is a small player in a competitive market, relying on the success of its pipeline to gain a stronger foothold.
Growth Trajectory and Initiatives
Historical Growth: As a clinical stage pharmaceutical, the company has not had significant revenue growth. Growth relies on clinical trial results.
Future Projections: Future growth is highly dependent on the success of its clinical trials and potential partnerships or acquisitions.
Recent Initiatives: Processa is conducting Phase 2 trials for Procetinostat and is launching clinical trials utilizing off-label capecitabine to optimize efficacy with lower doses for patients.
Summary
Processa Pharmaceuticals is a high-risk, high-reward biopharmaceutical company. Its strength lies in its pipeline of novel cancer therapies, but it faces significant challenges related to funding, clinical trial success, and competition. Positive clinical trial results and strategic partnerships are crucial for its future growth, but potential investors should be prepared for volatility and the inherent risks of drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is subject to change and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Processa Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Hanover, MD, United States | ||
IPO Launch date 2017-10-10 | CEO & Director Mr. George K. Ng Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | |
Full time employees 10 | |||
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.